The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients

Objective: To examine the kinetics of B cell subsets and activation markers in the early stage of belimumab treatment and their correction with treatment response. Methods: We enrolled 27 systemic lupus erythematosus (SLE) patients receiving 6 months belimumab treatment. Flow cytometry was used to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Ju, Bomiao, Zhu, Li, Li, Hanchao, Luo, Jing, Zhang, Jing, Hu, Nan, Mo, Lingfei, Wang, Yanhua, Pan, Ying, Huang, Jing, Lv, Xiaohong, Pu, Dan, Hao, Zhiming, He, Lan, Li, Yuanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978353/
https://www.ncbi.nlm.nih.gov/pubmed/36873989
http://dx.doi.org/10.3389/fphar.2023.1080730

Ejemplares similares

Ejemplares similares